EUVIMEDEUVIMED entdecken
Open Access

Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression

Johannes F Fahrmann, Amanda R Wasylishen, Carolina R C Pieterman, Ehsan Irajizad, Jody Vykoukal, Ranran Wu, Jennifer B Dennison iD, Christine B Peterson, Hua Zhao, Kim-Anh Do, Daniel M Halperin, Sunita K Agarwal und 14 weitere

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Johannes F Fahrmann und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Multiple Endocrine Neoplasia Type 1, Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with multiple endocrine neoplasia type 1 (MEN1) are predisposed to develop duodenopancreatic neuroendocrine tumors (dpNETs), and metastatic dpNET is the primary cause of disease-related mortality. Presently, there is a paucity of prognostic factors that can reliably identify patients with MEN1-related dpNETS who are at high risk of distant metastasis. In the current study, we aimed to establish novel circulating molecular protein signatures associated with disease progression. Experimental Design Mass spectrometry-based proteomic profiling was conducted on plasmas procured through an international collaboration between MD Anderson Cancer Center, the National Institutes of Health, and the University Medical Center Utrecht from a cohort of 56 patients with MEN1 [14 with distant metastasis dpNETs (cases) and 42 with either indolent dpNETs or no dpNETs (controls)]. Findings were compared to proteomic profiles generated from serially collected plasmas from a mouse model of Men1-pancreatic neuroendocrine tumors (Men1fl/flPdx1-CreTg) and control mice (Men1fl/fl).

Results

A total of 187 proteins were found to be elevated in MEN1 patients with distant metastasis compared to controls, including 9 proteins previously associated with pancreatic cancer and other neuronal proteins. Analyses of mouse plasmas revealed 196 proteins enriched for transcriptional targets of oncogenic MYCN, YAP1, POU5F1, and SMAD that were associated with disease progression in Men1fl/flPdx1-CreTg mice. Cross-species intersection revealed 19 proteins positively associated with disease progression in both human patients and in Men1fl/flPdx1-CreTg mice.

Conclusions

Our integrated analyses identified novel circulating protein markers associated with disease progression in MEN1-related dpNET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPancreatic NeoplasmsAnimalsHumansMiceDisease ProgressionProteomicsProto-Oncogene Proteins

Stichwörter der Autor:innen

biomarkersduodenopancreatic neuroendocrine tumorsmultiple endocrine neoplasia type 1prognosis

Substanzen

Men1 protein, mouseProto-Oncogene ProteinsMEN1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.
  • Department of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht 3508 GA, the Netherlands.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Jennifer B Dennison, Smita Jha, Hiroyuki Katayama

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • The University of Texas MD Anderson Cancer Center
  • Pancreatic Cancer Research
  • Neuroendocrine Tumor Research Foundation
  • National Institutes of Health

Zitieren

APA

Fahrmann, J. F., Wasylishen, A. R., Pieterman, C. R. C., Irajizad, E., Vykoukal, J., Wu, R., Dennison, J. B., Peterson, C. B., Zhao, H., Do, K. A., Halperin, D. M., Agarwal, S. K., Blau, J. E., Jha, S., Rivero, J. D., Nilubol, N., Walter, M. F., Welch, J. M., Weinstein, L. S., …, & Katayama, H. (2023). Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad315

Vancouver

Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Wu R, et al. Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad315

BibTeX
@article{Fahrmann2023,
  author = {Fahrmann, Johannes F and Wasylishen, Amanda R and Pieterman, Carolina R C and Irajizad, Ehsan and Vykoukal, Jody and Wu, Ranran and Dennison, Jennifer B and Peterson, Christine B and Zhao, Hua and Do, Kim-Anh and Halperin, Daniel M and Agarwal, Sunita K and Blau, Jenny E and Jha, Smita and Rivero, Jaydira Del and Nilubol, Naris and Walter, Mary F and Welch, James M and Weinstein, Lee S and Vriens, Menno R and van Leeuwaarde, Rachel S and van Treijen, Mark J C and Valk, Gerlof D and Perrier, Nancy D and Hanash, Samir M and Katayama, Hiroyuki},
  title = {Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad315}
}
Kostenlos starten →